{
  "background_dashed": [
    {
      "x": "Adolescents",
      "y": "Overall ASD symptoms",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 2,
      "pointRadius": 10,
      "Outcome_group": "Core ASD symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Overall ASD symptoms<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Restricted/repetitive behaviors",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 2,
      "pointRadius": 10,
      "Outcome_group": "Core ASD symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Restricted/repetitive behaviors<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Social-communication",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 2,
      "pointRadius": 10,
      "Outcome_group": "Core ASD symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Social-communication<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Adverse events",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 2,
      "pointRadius": 10,
      "Outcome_group": "Safety",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>no difference between SULFO and controls<\/b> on <u>Adverse events<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "ADHD symptoms",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 2,
      "pointRadius": 10,
      "Outcome_group": "Psych. comorbidity",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>ADHD symptoms<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Disruptive behaviors",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 2,
      "pointRadius": 10,
      "Outcome_group": "ASD-related symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Disruptive behaviors<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    }
  ],
  "background": [
    {
      "x": "Adolescents",
      "y": "Overall ASD symptoms",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 0,
      "pointRadius": 10,
      "Outcome_group": "Core ASD symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Overall ASD symptoms<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Restricted/repetitive behaviors",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 0,
      "pointRadius": 10,
      "Outcome_group": "Core ASD symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Restricted/repetitive behaviors<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Social-communication",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 0,
      "pointRadius": 10,
      "Outcome_group": "Core ASD symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Social-communication<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Adverse events",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 0,
      "pointRadius": 10,
      "Outcome_group": "Safety",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>no difference between SULFO and controls<\/b> on <u>Adverse events<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "ADHD symptoms",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 0,
      "pointRadius": 10,
      "Outcome_group": "Psych. comorbidity",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>ADHD symptoms<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    },
    {
      "x": "Adolescents",
      "y": "Disruptive behaviors",
      "backgroundColor": "rgba(255,255, 255, 0)",
      "borderColor": "#ff8b1a",
      "borderWidth": 0,
      "pointRadius": 10,
      "Outcome_group": "ASD-related symptoms",
      "customLabel": "In Adolescents (13-19 years old)  participants, there is <b>a small-to-moderate effect in favor of SULFO<\/b> on <u>Disruptive behaviors<\/u>. Based on the analysis of the quality of the evidence produced by the 2 clinical trials exploring this effect, we have a <b>very low confidence<\/b> in the estimation of this effect.",
      "n_studies": 2
    }
  ],
  "main": [
    {
      "x": "Adolescents",
      "y": "Overall ASD symptoms",
      "r": 8,
      "backgroundColor": "#A2CDAE",
      "borderWidth": 0,
      "Outcome_group": "Core ASD symptoms"
    },
    {
      "x": "Adolescents",
      "y": "Restricted/repetitive behaviors",
      "r": 8,
      "backgroundColor": "#A2CDAE",
      "borderWidth": 0,
      "Outcome_group": "Core ASD symptoms"
    },
    {
      "x": "Adolescents",
      "y": "Social-communication",
      "r": 8,
      "backgroundColor": "#A2CDAE",
      "borderWidth": 0,
      "Outcome_group": "Core ASD symptoms"
    },
    {
      "x": "Adolescents",
      "y": "Adverse events",
      "r": 8,
      "backgroundColor": "#D4D4D4",
      "borderWidth": 0,
      "Outcome_group": "Safety"
    },
    {
      "x": "Adolescents",
      "y": "ADHD symptoms",
      "r": 8,
      "backgroundColor": "#A2CDAE",
      "borderWidth": 0,
      "Outcome_group": "Psych. comorbidity"
    },
    {
      "x": "Adolescents",
      "y": "Disruptive behaviors",
      "r": 8,
      "backgroundColor": "#A2CDAE",
      "borderWidth": 0,
      "Outcome_group": "ASD-related symptoms"
    }
  ],
  "star": [
    {
      "backgroundColor": "red",
      "borderColor": "#red"
    }
  ],
  "xLabels": ["Pre-school", "School-age", "Adolescents", "Adults"],
  "yLabels": ["Overall ASD symptoms", "Social-communication", "Restricted/repetitive behaviors", "Sensory Profile", "", "Acceptability", "Tolerability", "Adverse events", "", "Global cognition (IQ)", "Adaptive behaviors", "Quality of life", "Language (Overall skills)", "Language (Expressive skills)", "Language (Receptive skills)", "", "ADHD symptoms", "Anxiety", "Mood related symptoms", "", "Disruptive behaviors", "Sleep quality", "Sleep quantity"]
}
